Aurinia Pharmaceuticals

AUPHApproved

Aurinia Pharmaceuticals is a commercial-stage biopharmaceutical company dedicated to delivering new treatment options to patients with autoimmune diseases. Its primary achievement is the FDA approval and commercialization of LUPKYNIS (voclosporin), a novel calcineurin inhibitor for lupus nephritis, a serious kidney manifestation of systemic lupus erythematosus. The company is strategically focused on maximizing the commercial potential of LUPKYNIS while exploring its application in other autoimmune indications. Aurinia's mission centers on addressing significant unmet medical needs in nephrology and rheumatology.

Market Cap

$263.3M

Employees

200-500

Focus

Biotech

AUPH · Stock Price

USD 1.982.02 (-50.50%)

Historical price data

AI Company Overview

Technology Platform

Next-generation calcineurin inhibitor platform focused on structural optimization for improved pharmacokinetic/pharmacodynamic predictability and tolerability in autoimmune diseases.

Pipeline Snapshot

18 drugs in pipeline, 9 in Phase 3

Drug	Indication	Stage
Voclosporin + Placebo Oral Capsule	Lupus Nephritis	Phase 3
voclosporin	Psoriasis	Phase 3
voclosporin	Adolescent Lupus Nephritis	Phase 3
voclosporin + Placebo	Psoriasis	Phase 3
voclosporin + Ciclosporin + Placebo	Psoriasis	Phase 3

Funding History

Total raised: $125M

PIPE$125MRA Capital ManagementJan 15, 2017

IPOUndisclosedUndisclosedOct 15, 2009

FDA Approved Drugs

LUPKYNISNDAJan 22, 2021

Opportunities

Growth opportunities include expanding the market share of LUPKYNIS in lupus nephritis through increased physician adoption and potential label expansions based on long-term data.

Ex-US commercialization via the Otsuka partnership represents a significant revenue opportunity.

The AUR200 pre-clinical platform offers a long-term opportunity to diversify into other B-cell mediated autoimmune diseases.

Risk Factors

Key risks include commercial execution challenges for LUPKYNIS, intense competition from GSK's Benlysta, high dependency on a single product for revenue, and pipeline setbacks as evidenced by the discontinuation of the dry eye program.

Achieving profitability on the anticipated timeline is also a critical challenge.

Competitive Landscape

Aurinia's main competitor in lupus nephritis is GlaxoSmithKline's Benlysta (belimumab). Differentiation is based on LUPKYNIS's oral administration, robust renal response data, and its role as an add-on therapy. The company also competes with generic standard-of-care immunosuppressants and faces potential future competitors in its pipeline areas.

Publications

Patents

Pipeline

FDA Approvals